Crystal Adam, the President of Research and Development at Tango Therapeutics, Inc., has reported significant stock transactions in a recent SEC filing. On October 1, 2026, Adam engaged in multiple trades involving common stock, which are part of a broader strategy within the pharmaceutical preparations industry.
Tango Therapeutics, Inc., identified by its CIK number 0001819133, operates in the pharmaceutical preparations sector, focusing on innovative therapies. The company is listed under the SIC code 2834, which encompasses a wide range of pharmaceutical products. Recent filings show that Adam has been active in trading, with the latest report being filed on October 5, 2026, under accession number 0001193125-26-414500.
What the Filing Says
The filing details three notable transactions executed by Adam on October 1, 2026. Firstly, Adam acquired 27,000 shares of common stock at a price of $5.20 per share. Following this acquisition, Adam's total ownership increased to 142,743 shares.
In addition, Adam sold 26,400 shares at a weighted average price of $24.4547, which resulted in a new total of 116,343 shares owned after the sale. Another sale involved 600 shares at a price of $25.32, bringing the total down to 115,743 shares.
Furthermore, Adam exercised stock options to acquire an additional 27,000 shares, which will vest over a four-year period. This transaction further increased Adam's ownership to 233,040 shares of common stock.
Impact
These transactions may influence investor perceptions of Tango Therapeutics, particularly regarding management's confidence in the company's future. Adam's active trading could signal a strategic repositioning or response to market conditions. Stakeholders, including investors and analysts, will likely be monitoring these developments closely.
What's Next
The filing does not say what happens next. However, the ongoing trading activity may lead to further disclosures in upcoming filings as Adam continues to manage her holdings in Tango Therapeutics.